Faron Pharmaceuticals Oy (FRA:4FR) Moat Score: 0/10 (As of Jul. 06, 2026)


FRA:4FR Faron Pharmaceuticals Oy FRA:4FR
21 GF Score
Price €0.51
! 4 Warning Signs
View Full Analysis

What is Faron Pharmaceuticals Oy Moat Score?

Faron Pharmaceuticals Oy has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Faron Pharmaceuticals Oy has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Faron Pharmaceuticals Oy might have No Moat - No discernible moat.

Faron Pharmaceuticals Oy  (FRA:4FR) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Faron Pharmaceuticals Oy Moat Score Related Terms

FRA:4FR
21GF Score
Faron Pharmaceuticals Oy FRA:4FR
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faron Pharmaceuticals Oy Business Description

Other Exchanges FARN:UKFARON:Finland
Address Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
21GF Score

Get the complete analysis for FRA:4FR

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price